BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17973783)

  • 1. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
    Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
    Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
    Konjević G; Jović V; Radomirović V; Spuzić I
    Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
    Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
    Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease.
    Hervier B; Beziat V; Haroche J; Mathian A; Lebon P; Ghillani-Dalbin P; Musset L; Debré P; Amoura Z; Vieillard V
    Arthritis Rheum; 2011 Jun; 63(6):1698-706. PubMed ID: 21370226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells.
    Clausen J; Vergeiner B; Enk M; Petzer AL; Gastl G; Gunsilius E
    Immunobiology; 2003; 207(2):85-93. PubMed ID: 12675266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic profiles of peripheral blood lymphocytes on the day of embryo transfer in women undergoing in vitro fertilization.
    Baczkowski T; Kurzawa R
    Folia Histochem Cytobiol; 2007; 45 Suppl 1():S73-7. PubMed ID: 18292839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed analysis of peripheral blood natural killer (NK) cells in women with recurrent miscarriage.
    King K; Smith S; Chapman M; Sacks G
    Hum Reprod; 2010 Jan; 25(1):52-8. PubMed ID: 19819893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.
    Konjevic G; Mirjacic-Martinovic K; Vuletic A; Babovic N
    J BUON; 2012; 17(4):761-9. PubMed ID: 23335538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients.
    Mirjačić Martinović K; Konjević G; Babović N; Inić M
    J Surg Res; 2011 Dec; 171(2):637-49. PubMed ID: 20828749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells.
    Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ
    Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
    Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
    Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.
    Hudspeth K; Donadon M; Cimino M; Pontarini E; Tentorio P; Preti M; Hong M; Bertoletti A; Bicciato S; Invernizzi P; Lugli E; Torzilli G; Gershwin ME; Mavilio D
    J Autoimmun; 2016 Jan; 66():40-50. PubMed ID: 26330348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
    Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
    Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
    Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
    Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.